The University of Pittsburgh School of Medicine is the medical school of the University of Pittsburgh, located in Pittsburgh, Pennsylvania. The School of Medicine, also known as Pitt Med, is consistently ranked as a "Top Medical School" by U.S. News & World Report in both research and primary care.

During the past decade, University of Pittsburgh School of Medicine conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 12 clinical trials were completed, i.e. on average, 63.2% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 7 clinical trials were completed. i.e. 77.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Pittsburgh School of Medicine" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 16 trials, followed by "University of Pittsburgh" with 10 trials sponsored, "Human Genome Sciences Inc." with 4 trials sponsored, "Knopp Biosciences" with 3 trials sponsored and "Actelion" with 3 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 36 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Pittsburgh School of Medicine" #1 collaborator was "Bristol-Myers Squibb" with 5 trials as a collaborator, "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 4 trials as a collaborator, "University of Pittsburgh" with 3 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator and "National Cancer Institute (NCI)" with 2 trials as a collaborator. Other collaborators include 14 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "University of Pittsburgh School of Medicine" are "HIV Infections" (19 trials), "Obesity" (3 trials), "Amyotrophic Lateral Sclerosis" (2 trials), "Breast Cancer" (2 trials) and "Contraception" (2 trials). Many other conditions were trialed in "University of Pittsburgh School of Medicine" in a lesser frequency.

Most popular intervention types in "University of Pittsburgh School of Medicine" are "Drug" (43 trials), "Behavioral" (7 trials), "Biological" (7 trials), "Procedure" (6 trials) and "Other" (5 trials). Other intervention types were less common.

The name of intervention was led by "Zidovudine" (14 trials), "Placebo" (6 trials), "Didanosine" (5 trials), "Aldesleukin" (2 trials) and "Belimumab 1 mg/kg" (2 trials). Other intervention names were less common.

The vast majority of trials in "University of Pittsburgh School of Medicine" are 59 trials for "All" genders, 10 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "University of Pittsburgh School of Medicine". 1 are not yet recruiting, 6 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 55 completed trials in University of Pittsburgh School of Medicine, 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in University of Pittsburgh School of Medicine, 11 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 18 trials that are defined as “Not Applicable".